Efficacy and safety of GV1001 in patients with moderate-to-severe Alzheimer's disease already receiving donepezil: a phase 2 randomized, double-blind, placebo-controlled, multicenter clinical trial

• Published in: Alzheimer's research & therapy 2021-03, Vol.13 (1), p.66-66, Article 66
• Main Authors: Koh, Seong-Ho, Kwon, Hyuk Sung, Choi, Seong Hye, Jeong, Jee Hyang, Na, Hae Ri, Lee, Chan Nyoung, Yang, YoungSoon, Lee, Ae Young, Lee, Jae-Hong, Park, Kyung Won, Han, Hyun Jeong, Kim, Byeong C, Park, Jin Se, Lee, Jee-Young, Kim, Sangjae, Lee, Kyu-Yong
• Format: Article
• Language: English
• Subjects: Activities of daily living; Alzheimer's disease; Amyloid beta-protein; Care and treatment; Clinical trial; Clinical trials; Dementia; Development and progression; Double-blind studies; Drug dosages; Efficacy; Evaluation; FDA approval; Gene expression; Genetic aspects; GV1001; Health aspects; Magnetic resonance imaging; Safety
• ISSN: 1758-9193; 1758-9193
• DOI: 10.1186/s13195-021-00803-w

Our previous studies showed that GV1001 has various protective effects against β-amyloid and other stressors. Based on these findings, we hypothesized that GV1001 might have beneficial effects in patients with Alzheimer's disease (AD). A phase 2, double-blind, parallel-group, placebo-controlled, 6-month randomized clinical trial was performed to evaluate the safety and efficacy of subcutaneously administered GV1001. Between September 2017 and September 2019, 13 centers in South Korea recruited participants. A total of 106 patients were screened, and 96 patients with moderate-to-severe AD were randomized 1:1:1 to the placebo (group 1, n = 31), GV1001 0.56 mg (group 2, n = 33), and 1.12 mg (group 3, n = 32) groups. GV1001 was administered every week for 4 weeks (4 times), followed by every 2 weeks until week 24 (10 times). The primary endpoint was the change in the Severe Impairment Battery (SIB) score from baseline to week 24. The key secondary efficacy endpoints were the change in the Clinical Dementia Rating Sum of Box (CDR-SOB), Alzheimer's Disease Cooperative Study-Activities of Daily Living (ADCS-ADL), Neuropsychiatric Inventory (NPI), Mini-Mental State Examination, and Global Deterioration Scale scores. The safety endpoints were also assessed based on adverse events, laboratory test results, vital signs, and other observations related to safety. Group 3 showed less decrease in the SIB score at 12 and 24 weeks compared with group 1 (P